Filing Details

Accession Number:
0000950170-23-039299
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-07 21:39:25
Reporting Period:
2023-08-03
Accepted Time:
2023-08-07 21:39:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661998 Homology Medicines Inc. FIXX Pharmaceutical Preparations (2834) 473468154
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1968554 Julie Jordan C/O Homology Medicines, Inc.
One Patriots Park
Bedford MA 01730
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-03 1,548 $0.00 4,318 No 4 M Direct
Common Stock Disposition 2023-08-03 436 $1.39 3,882 No 4 S Direct
Common Stock Acquisiton 2023-08-03 387 $0.00 4,269 No 4 M Direct
Common Stock Disposition 2023-08-03 109 $1.39 4,160 No 4 S Direct
Common Stock Acquisiton 2023-08-03 4,644 $0.00 8,804 No 4 M Direct
Common Stock Disposition 2023-08-03 1,308 $1.39 7,496 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-08-03 1,548 $0.00 1,548 $0.00
Common Stock Restricted Stock Units Disposition 2023-08-03 387 $0.00 387 $0.00
Common Stock Restricted Stock Units Disposition 2023-08-03 4,644 $0.00 4,644 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
0 No 4 M Direct
0 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.
  2. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on May 27, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported restricted stock units.
  3. The sales reported in the Form 4 were effected pursuant to a mandatory sell to cover arrangement solely with the intent to cover taxes in connection with the vesting of certain previously reported restricted stock units.
  4. Vesting for a portion of the restricted stock units was accelerated and such portion vested and settled on August 3, 2023. The restricted stock units would otherwise have vested and settled as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025. The remaining restricted stock units have been automatically cancelled and forfeited.
  5. Vesting for a portion of the restricted stock units was accelerated and such portion vested and settled on August 3, 2023. The restricted stock units would otherwise have vested and settled as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such restricted stock units would have become fully vested on January 1, 2026. The remaining restricted stock units have been automatically cancelled and forfeited.